

Breakthroughs

Spotlighting New Discovery in Brain Cancer Research

March 2012

UCLA to host 12th Annual Brain Tumor Conference March 23rd & 24th 2012

FREE REGISTRATION FOR PATIENTS,
PHYSICIANS AND CARE GIVERS

Art of the Brain Annual Gala “The Art of Care Giving”

Phase I Studies: AMG-595 (Amgen) ; GDC-0084 (Genentech) for Patients With Recurrent Diagnosed Glioblastoma Multiforme

Phase II Study: Bortezomib (VELCADE) for Patients With Newly Diagnosed Glioblastoma Multiforme

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

LATEST JOURNAL ARTICLES AT:

NEUROONCOLOGY.UCLA.EDU



ONCOGENIC EGFR SIGNALING ACTIVATES AN
MTORC2-NF-KB PATHWAY THAT PROMOTES
CHEMOTHERAPY RESISTANCE.



3'-DEOXY-3'-18F-FLUOROTHYMININE PET AND MRI
FOR EARLY SURVIVAL PREDICTIONS IN PATIENTS
WITH RECURRENT MALIGNANT GLIOMA TREATED
WITH BEVACIZUMAB.



FUNCTIONAL DIFFUSION MAPS (FDMS) EVALUATED
BEFORE AND AFTER RADIOCHEMOTHERAPY PRE-
DICT PROGRESSION-FREE AND OVERALL SURVIVAL IN
NEWLY DIAGNOSED GLIOBLASTOMA.





Clinical Trials Opportunities for Patients with Recurrent Malignant Gliomas

Phase II Study: Bortezomib (VELCADE) for Patients With Newly Diagnosed Glioblastoma Multiforme

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin

2012 Clinical Trials Now Enrolling

Dani Saleh Brain Cancer Research Fund at UCLA

UCLA Fellowship Program - Training Tomorrow's Neuro-Oncologist

Art of the Brain 12th Annual Gala - 'The Art of Care Giving'

UCLA Neuro-Oncology to host 12th Annual Brain Tumor Conference March 23rd-24th, 2012

DIRECTORS MESSAGE

In this issue of Breakthroughs I am proud to share with you some of the advances that are moving us closer toward a cure for brain cancer.

First, I would like to highlight new approaches toward fighting brain cancer found on page 4. We are one of only three institutions in the world to evaluate these new experimental approaches that were developed specifically for recurrent brain cancer (tumors progressing after initial therapies).

These are both first in human studies. GDC0084 is a PI3K/mTOR kinase inhibitor that has been explicitly developed to penetrate the blood brain barrier and gain access to the tumor. The second is AMG595, a fully humanized antibody against the mutated receptor EGFR-vIII, that is only present on tumor cells of glioblastoma and not on normal cells. Attached to this antibody is an extremely potent antitubulin inhibitor making this agent very toxic selectively to brain cancer.

Additionally, we are featuring a new clinical trial of treating newly diagnosed glioblastoma with the proteasome inhibitor bortezomib added to the standard of care approach of radiation and chemotherapy.

I also want to share with you some of our groundbreaking research. Although we have published over 30 research articles this past year, I wanted to draw special attention to two publications. The first is from UCLA's internationally renowned researcher Dr. Paul Mischel showing how the inhibition of a target, TORC2, in glioblastoma cells reverses chemotherapy resistance and is on the fast track to the clinic. Additionally a paradigm changing research finding by Dr. Albert Lai regarding IDH mutated tumors has provided the framework to begin understanding how to best treat these unique gliomas. Finally it is a pleasure to spotlight Neuro-Oncology Training Program under the direction of Dr. Leia Nghiemphu.

We are excited to be presenting our 12th Annual Brain tumor conference for patients and their care givers. This event will take place on March 23rd and 24th, 2012 at UCLA. Please use the information at the end of this



newsletter to register now so that we can effectively accommodate all who want to attend. Additionally, I wanted to bring your attention to our caregiver support group featured on page 12 which is run by our talented social workers, Cheryl Abe and Pam Hoff.

Finally, we want to give special thanks to those who support our research each and every year through the Art of the Brain Annual Gala. We also wish to thank those who give through memorial funds and various fundraising events benefiting UCLA Neuro-Oncology. If you would like to support the program at an upcoming events, please join us at the Cranium Crusaders Annual Pub Night and Memorial 5K Run that will take place on April 26th and May 12th, 2012.

Please visit <http://neurooncology.ucla.edu> for the most up to date information.

Thank you for taking the time to read Breakthroughs and thank you for partnering with us in our quest to cure brain cancer.

Timothy Cloughesy M.D.
Program Director; Neuro-Oncology
UCLA Medical Center

Clinical Trials Opportunities for Patients with Recurrent Malignant Gliomas

Phase I: AMG-595 (Amgen); GDC-0084 (Genentech)

Two new clinical trials for patients with recurrent malignant gliomas will soon be available through the UCLA Neuro-Oncology Program. Both are Phase I trials studying agents AMG-595 (sponsored by Amgen, Inc.) and GDC-0084 (sponsored by Genentech, Inc.).

Brain cancer is a complicated web of molecular structures and pathways, and recent scientific research has uncovered some of the mysteries that lie behind it. Scientists have discovered particular gene mutations that exist in cancer cells. These genetic alterations can activate cellular pathways that lead to the development of brain cancer. In response, researchers are developing molecularly targeted treatments to arrest the progression of cancer cells.

One of those therapies that will soon be offered in a clinical trial setting at UCLA is sponsored by Amgen Inc, focusing on the antibody drug conjugate (ADC) AMG-595. AMG-595 targets the epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutation of the epidermal growth factor receptor (EGFR) for epidermal growth factor protein ligands. EGFR is overexpressed

in 40-50% of patients with glioblastoma multiforme, with EGFRvIII as the most common mutation of this gene. The presence of EGFRvIII in cancer can activate downstream phosphatidylinositol 3-kinase pathway activation, which in turn promotes tumor growth.

The experimental drug is designed to deliver a potent anti-EGFRvIII antibody to the tumor. This ADC works by binding to the EGFR variant, and is then internalized into the tumor cell. This internalization leads to mitotic arrest, inhibiting tumor growth. Preclinical studies have shown a positive response to EGFRvIII.

UCLA will soon be conducting a Phase Ia clinical trial studying the use of AMG-595 in patients with recurrent malignant gliomas. It is a first-in-human study that will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the experimental drug on patients with the disease. This study will be conducted in two parts: dose exploration and dose expansion. Approximately 60 patients are expected to be enrolled in this study. Patients must be at least 18 years

of age, have 1st or 2nd recurrent GBM or AA tumor following initial therapy, have a Karnofsky Performance Score (KPS) equal to or greater than 70%, have tumors that show evidence of expression of receptor EGFRvIII and have a life expectancy of at least 3 months, among other criteria.

In part 1 of the study, AMG-595 will be administered via intravenous infusion once every 3 weeks. After the first 2 doses and upon successful completion of a 28-day window for assessment of dose-limiting toxicities, patients will then receive an MRI during week 5 of treatment. The next dose of AMG 595 can resume at Week 7 unless there is a progression of disease or patient displays clinical progression. MRIs will continue at Week 9 and every 8 weeks thereafter. Upon completion of this phase of the study, researchers will then conduct a dose expansion study to further evaluate the study drug.

Another promising experimental study that will be conducted at UCLA is the study of therapeutic agent GDC-0084. This clinical trial, sponsored by Genentech, Inc., will use GDC-0084 to target

For more information about these upcoming clinical trials and others that are currently being offered by the UCLA Neuro-Oncology Program, please contact Emese Filka at (310) 794-3521

the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/mTOR) pathway.

PI3K pathway activation by genetic alterations is common in gliomas. PI3K activation signals AKT, which then activates mTOR. Overactivity of this pathway reduces apoptosis and promotes cell proliferation. Scientists believe that GDC-0084 will be able to inhibit and suppress the signaling within this pathway that causes tumor growth.

GDC-0084 is a small molecular inhibitor of class I PI3K and mTOR kinase. This experimental agent is designed to cross the blood-brain barrier to achieve high exposure of the drug to the brain tumor. Studies have shown that it is a significant brain penetrant with po-

tent, selective inhibition of class I PI3K, as well as inhibited human mTOR. It has also shown potency in inhibiting growth on human glioma cell line panels

UCLA will be soon be offering the Phase I clinical trial of GDC-0084, as part of a multi-center effort. Patients who are at least 18 years old and are diagnosed with a recurrent high-grade glioma (WHO Grade III-IV) that have previously received prior treatment are eligible. Patients must also have a KPS equal to or greater than 70% and adequate hematologic and organ function. The trial is a two-stage, first-in-human study that will evaluate the safety, tolerability and pharmacokinetics of GDC-0084, to determine the maximum-tolerated dose and to characterize the dose-limiting toxicities of the drug.

Patients enrolled in this study will receive the drug orally in capsule form. In Stage 1, the first treatment of this study entails a 35 day treatment cycle. Study patients will receive a dose of GDC-0084 on Day 1 of the cycle, then daily doses beginning on Day 8 until Day 35. Cycle 2 and subsequent cycles are 28 days long with daily doses of the study medication. Those patients who are enrolled in Stage 2 will receive daily dosing of the study drug in 28 days cycles.

For more information about these upcoming clinical trials and others that are currently being offered by the UCLA Neuro-Oncology Program, please contact Emese Filka at (310) 794-3521.



Timothy Cloughesy M.D.
Program Director; Neuro-Oncology
UCLA Medical Center

Phase II Study: Bortezomib (VELCADE) for Patients With Newly Diagnosed Glioblastoma Multiforme

UCLA Neuro-Oncology has recently begun enrolling patient in an investigator-initiated Phase II study examining the efficacy and safety of bortezomib (VELCADE), temozolomide, and radiation therapy followed by bortezomib and temozolomide after completion of radiation.

The study will be supported by Millenium Pharmaceuticals and will be an open-label study for newly-diagnosed adult patients with glioblastoma that have not received therapy other than surgery. Enrollment is limited to 50 patients over two years.

The objectives of the study are to estimate the overall and progression-free survival in patients with newly-diagnosed glioblastoma treated with bortezomib/temozolomide/radiation followed by bortezomib/temozolomide until progression is detected or for up to 24 cycles (~2 years).

Additionally, a key enrollment inclusion criterion is the collection of frozen and paraffinized tumor tissue. This will provide samples for correlative studies aimed at understanding molecular features that may predict a response to treatment.

Bortezomib, is a reversible inhibitor of the proteasome, which plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Bortezomib has gained FDA approval for myeloma in the relapsed and frontline setting and in relapsed mantle cell lymphoma. Inhibition of the proteasome can affect multiple

signaling cascades within the cell, and, most notably, bortezomib is the only clinically available inhibitor of NF- κ B signaling. Therefore, this trial is poised to provide clinical relevance to the recent landmark finding that 25% of glioblastoma harbor a genetic alteration leading to dysregulated NF- κ B signaling.

In this study, patients will receive 1.3 mg/m² bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide 75 mg/m² daily during radiation. Bortezomib will be administered beginning on the first day of radiation with temozolomide. External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. After a 2-6 week rest (for temozolomide and bortezomib) following completion of radiation therapy, a maintenance phase (post-RT) of temozolomide will be restarted at 150-200 mg/ m²/day for 5 days out of every 28. Also, bortezomib at 1.3 mg/ m² will given on days 1, 4, 8, and 11 of a 28 day cycle commencing on the first day of temozolomide. Treatment with bortezomib and temozolomide will continue for 24 additional 28 day cycles from radiation therapy if there is no evidence of progression. At that time, both bortezomib and temozolomide will be stopped if there is no evidence of disease progression. Some of the anticipated side effects include lowering of blood counts, fatigue, nausea, and peripheral neuropathy.

For more information about this clinical trial and others that are currently being offered by the UCLA Neuro-Oncology Program, please contact Emese Filka at (310) 794-3521

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin


In the December 1, 2011 edition of the Journal of Clinical Oncology, Dr. Lai and co-authors published an important article describing a detailed dissection of the molecular events resulting in glioblastomas harboring the IDH1 mutation. This large work represented a collaborative effort of numerous investigators at UCLA and Dr. Heidi Phillips and her colleagues at Genentech.

In this study which examined tumor tissue, imaging, and clinical outcomes for over 600 glioblastoma patients, the authors conclude that IDH1R132MUT GBMs arise via a sequenced series of molecular alterations from a restricted progenitor cell type involved in late frontal lobe maturation. These findings have widespread implications in our understanding of how some glioblastomas arise and how they may be attacked.

PURPOSE: Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1(R132MUT)) is frequent in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a marker for GBMs that arise by transformation from lower-grade gliomas, regardless of clinical history. To determine how GBMs arising with IDH1(R132MUT) differ from other GBMs, we undertook a comprehensive comparison of patients presenting clinically with primary GBM as a function of IDH1(R132) mutation status.

PATIENTS AND METHODS: In all, 618 treatment-naïve primary GBMs and 235 lower-grade diffuse gliomas were sequenced for IDH1(R132) and analyzed for demographic, radiographic, anatomic, histologic, genomic, epigenetic, and transcriptional characteristics.

RESULTS: Investigation revealed a constellation of features that distinguishes IDH1(R132MUT) GBMs from other GBMs (including frontal location and lesser extent of contrast enhancement and necrosis), relates them to lower-grade IDH1(R132MUT) gliomas, and supports the concept that IDH1(R132MUT) gliomas arise from a neural precursor population that is spatially and tem-



ALBERT LAI MD, PHD : UCLA NEURO-ONCOLOGY

porally restricted in the brain. The observed patterns of DNA sequence, methylation, and copy number alterations support a model of ordered molecular evolution of IDH1(R132MUT) GBM in which the appearance of mutant IDH1 protein is an initial event, followed by production of p53 mutant protein, and finally by copy number alterations of PTEN and EGFR.

CONCLUSION: Although histologically similar, GBMs arising with and without IDH1(R132MUT) appear to represent distinct disease entities that arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events. Optimal clinical management should account for the distinction between these GBM disease subtypes.


Learn more about this journal article at <http://neurooncology.ucla.edu>

UCLA Neuro-Oncology: Clinical Trials Now Enrolling

Choosing to participate in a clinical trial is an important personal decision. It is often helpful to talk to a physician, family members or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

For more information about any of the UCLA Neuro-Oncology Program's clinical trials, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521.

UCLA IRB#	Study ID#	Protocol
11-000467	ABTC: 10-02	A Phase I/II Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma.
11-001673	DFCI (Dana Farber) 11-033	A Phase II study of BKM120 for subjects with recurrent glioblastoma and activated PI3K pathway at first relapse.
11-002957	Plexikkon: PLX108-04	A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma.
11-002219	Celgene CC-223-ST-001	A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects with Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma.
11-003256	Tocagen Tg 511-11-01	A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma and Followed by Treatment with Toca FC, Extended Release 5-FC.
10-001147	Tocagen Tg 511-09-01	A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511.
10-000484	Tocagen Tg 511-08-01	A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients with Recurrent Glioblastoma Multiforme.
10-001735	Exelixis XL765-002	A Phase 1 Dose-Escalation Study of XL765 in Combination with Temozolomide with and without Radiation in Subjects with Malignant Glioma.
10-000760	Nghiemphu: AVF4535s	Phase II Study of Bevacizumab and Temozolomide in Elderly Patients with Newly-Diagnosed Glioblastoma Multiforme.
09-03-084	Lai Lab: X05303	Phase II Trial of VELCADE® (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-Diagnosed Glioblastoma Multiforme.
10-000655	Cloughesy : Molecular Bio-Markers	Molecular Genetic Characterization of Human Brain Tumors.



Stan Nelson M.D.
Professor and Vice Chair of Human Genetics
David Geffen School of Medicine at UCLA

Dani Saleh Brain Cancer Research Fund at UCLA

The Dani Saleh Brain Cancer Research Fund supports the brain cancer research collaboration between Dr. Timothy Cloughesy and Dr. Stan Nelson. This fund will directly support the work and training of a research fellow in Dr. Stan Nelson's lab.

Dr. Nelson is Professor and Vice Chair of Human Genetics and Professor of Psychiatry at the David Geffen School of Medicine at UCLA.

Dr. Nelson's research focus is on technology development and application of genomics to cancer biology and

common human diseases with active research in brain cancer. His lab uses these genomic technologies to develop molecularly based classification schemes and provide leads for the development of novel targeted therapeutics for gliomas.

For more information on Dr. Nelson and his research, please visit his David Geffen School of Medicine at UCLA profile at: http://people.healthsciences.ucla.edu/research/institution/personnel?personnel_id=45469

Supporting the Dani Saleh Brain Can-

cer Research Fund at UCLA helps improve the understanding of brain cancer's molecular makeup and accelerate brain cancer research towards finding new therapeutic approaches to the disease.

UCLA Fellowship Program - Training Neuro-Oncologists

Paving the way for the next generation of Neuro-Oncologists, the UCLA Neuro-Oncology Fellowship Program continues its rich history as the premiere training program for those physicians interested in specializing in neuro-oncology.

The UCLA Neuro-Oncology Fellowship is a 2/3 year program providing excellence in clinical training with opportunities for cutting-edge clinical and research work. The fellowship training program is accredited by the United Council for Neurologic Subspecialties.

The first year is designed to allow the fellow to become familiar with the many aspects of the UCLA Neuro-Oncology Program. Fellows gain experience in treating patients with primary brain tumors through the adult brain tumor clinical rotation, and is responsible for the supervision and care of these patients. The fellow is also exposed to metastatic disease, pediatric neuro-oncology, CNS complications of systemic cancer through attending rotations of pediatric neuro-oncology, medical oncology and radiosurgery clinics. Knowledge regarding typical complications of therapy in general cancer patients will be gleaned from the setting.

The second/third year of the fellowship will require attending weekly continuity clinic and Brain Tumor Board. The fellow will also be asked to focus in an area of research, either bench or clinical.

UCLA Neuro-Oncology has been successful in training physicians to become experts in this field. Each graduate has continued their careers as Neuro-Oncologists, offering clinical care and contributing to the advancement of brain cancer research and treatments, while some have also become Directors of Neuro-Oncology in hospitals throughout the state.

Dr. Phioanh Leia Nghiemphu, UCLA Neuro-Oncology Fellowship Program Director, has successfully trained fellows who have passed their Neuro-Oncology Board Certification and are currently in Academic careers as Neuro-Oncologists. As the director, she has first-hand responsibility for daily training and teaching of the fellows. She designs the curriculum, presents weekly didactic lectures and provides daily clinical training to ensure their proper training as neuro-oncologists.

Dr. Nghiemphu, herself, received Neuro-Oncology training under the direction of Dr. Timothy Cloughesy, Director of the UCLA Neuro-Oncology Program. Since completing the Neuro-Oncology Fellowship Program, she has become a faculty member of the David Geffen School of Medicine at UCLA, Department of Neurology, as an Assistant Professor. She is a dedicated clinician with a commitment to the advancement of brain cancer research. Her research as a fellow, and as a faculty member, has contributed to the mobilization of brain cancer research progress. Most recently, she initiated two new clinical trials as Principal Investigator for patients with Glioblastoma Multiforme that are currently open for enrollment and open to several other cancer centers in California and New York.


Dr. Nghiemphu's experience and expertise in a wide array of professional activities (such as clinical care and research, medical student teaching, serving as a member of a medical institutional review board and a reviewer for professional medical journals), provides fellows with the enrichment needed to become well-rounded neuro-oncology medical providers. UCLA Neuro-Oncology fellows also receive mentorship from Neuro-Oncology attendings, Dr. Cloughesy and Dr. Albert Lai, both of whom are well-respected and

accomplished in the field of Neuro-Oncology.

As a leader in the field of brain cancer treatments and research, UCLA Neuro-Oncology Program provides a unique opportunity for those wishing to further their education and training in the Neuro-Oncology specialty.



Neuro-Oncology Fellow Dr. Ruben Guzman-Marín (bottom), Dr. Phioanh Leia Nghiempfu with Neurology Resident Dr. Michael Ho (left) in the clinical setting



Resources for Brain Tumor Caregivers and Families

Join UCLA's support group for caregivers, families and friends caring for patients with brain tumors.

A unique support system where one can gain strength from those with similar experiences.

2012 Meetings Dates:
March 8, April 12, May 10 and June 14.

The diagnosis of a brain tumor can be a life-altering experience for not only the individual diagnosed with the disease, but also for his or her family and friends. The diagnosis may affect the way families and friends go about their daily lives. Oftentimes, it is a close family member or friend who takes on the role of caregiver and the responsibility of providing assistance to his or her loved one during this difficult time. Whether the brain tumor is benign or malignant, the caregiver experience can be a difficult one depending on the level of care needed.

The role of the caregiver is an important one, as it includes providing emotional support to the patient, helping to

organize and accompany the patient to medical visits, making sure prescribed treatments and medications are taken, dealing with insurance issues, and coordinating any and all necessary protocols to make sure the patient is receiving proper care. At times it may seem a bit much to handle, but there are resources available that the caregiver can utilize to make the experience manageable.

One great source of support is the social worker, who can be found in hospitals or medical facilities where treatment is received, private practice, mental health and community agencies. Social workers can provide a wealth of information and guidance on the social and emotio-

nal needs of families and caregivers, and the economic problems that may arise from the diagnosis and treatments. They provide counseling and referrals to services that can help the caregiver simultaneously manage his or her normal life with the care he or she must provide for the patient.

It is important for the caregiver to know that he is not alone. At UCLA, a support group for caregivers, families and friends is available to those interested. Here, one can find a support system of those with similar experiences, and where one can gain strength and courage to continue to care for their loved one in need.





The UCLA Brain Tumor Caregiver Support Group meets monthly to provide support and guidance for the needs of the brain tumor caregiver. The group is facilitated by licensed clinical social workers, Cheryl Abe and Pamela Hoff, and normally meets on the second Thursday of each month.

Meetings dates planned for the first half of 2012 include: March 8, April 12, May 10 and June 14.

Meetings take place at the Radiation Oncology Department, located at 200 UCLA Medical Plaza, Level B2 from 6:30pm to 8:30pm.

Newcomers, prior to their first visit, are advised to call Cheryl Abe at (310) 206-6731 or email cabe@mednet.ucla.edu; and/or Pamela Hoff at (310) 825-6134 or email phoff@mednet.ucla.edu. Current group members should also RSVP for each meeting they plan to attend.

If you are unable to attend any of the support group meetings but wish to consult with a social worker, you may call either social worker listed above, or call the UCLA Neuro-Oncology Program at (310) 825-5321.

Further resources and support groups provided at UCLA can also be found through the UCLA Jonsson Compre-

hensive Cancer Center and the Simms/Mann Center at UCLA for Integrative Oncology. You may find more information on their respective websites: www.cancer.ucla.edu and www.simmsmanncenter.ucla.edu.

In addition to these UCLA resources, caregivers can find assistance through many local and national organizations offering support, educational information, counseling services, health and wellness classes, respite for caregivers, and advocacy.

Memorial Fund Giving - Building a legacy and funding a cure

In 2011, several memorial fundraisers were held benefiting brain cancer research at the UCLA Neuro-Oncology Program. These fundraisers were hosted by dedicated family members of patients treated at UCLA. Because of their hard work and dedication, their loved ones' legacies continue to live on. The UCLA Neuro-Oncology Program is thankful to our following friends.

The Beryl Companies hosted the 4th Annual Barry Spiegelman Memorial Golf Classic on April 12, 2011. The event was held at Sky Creek Ranch Golf Club in Keller, TX. The Beryl Companies was co-founded by Barry Spiegelman, former patient of Dr. Timothy Cloughesy, and his brother Paul Spiegelman. After years of battling a brain tumor Barry passed away in 2005, but his memory continues to live on with this annual event. Proceeds from the golf tournament were donated to Art of the Brain, the fundraising arm of the UCLA Neuro-Oncology Program.

Later that month on April 28th, the Cranium Crusaders held its first of two fundraisers of 2011. Cranium Crusaders is a support group of UCLA that



Beryl Companies hosted the 4th Annual Barry Spiegelman Memorial Golf Classic, April 12, 2011
Sky Creek Ranch Golf Club in Keller, TX.



4th Annual Pub Night at Legends on 2nd in
Long Beach, CA (Cris Zavaleta & Tim Cloughesy)

was formed by Cindy Atkinson and Cris Zavaleta to bring awareness to brain cancer and to raise money for research at UCLA. The organization's first event of the year was the 4th Annual Pub Night at Legends on 2nd in Long Beach, CA. The event was a celebration of the life of retired Long Beach Firefighter Hank Zavaleta. Zavaleta was a long time patient of the UCLA Neuro-Oncology Program and was an avid supporter of Dr. Cloughesy's research efforts.

The Cranium Crusaders held their second fundraiser the following month on May 7th. The 4th Annual Tom Atkinson 5k Run/Walk was held in Lakewood, CA. Tom Atkinson was also a patient of Dr. Cloughesy's. Unfortunately, he passed away in 2006 after battling the disease. Each year, the 5k event continues to grow and garner more supporters. In 2011, the Cranium Crusaders were able to raise more than \$70,000 for the UCLA Brain Cancer Research Fund.



4th Annual Tom Atkinson 5k Run/Walk
Lakewood, CA - May 7th, 2011
(Cris Zavaleta, Linda Liao, Cindy Atkinson & Tim Cloughesy)

On October 1, 2011, the 3rd Annual Brain Waves Swim Relay was held in San Diego, CA to benefit the Art of the Brain. The annual event is held in memory of Adam Balch and is coordinated by his brother Mac Balch. Adam was diagnosed with brain cancer while attending college at the University of California, Santa Cruz. Since Adam's diagnosis, Mac and his family have always been proactive in helping to find a cure for brain cancer by organizing local fundraisers for brain cancer research. In its third year, the annual Brain Waves swim relay raised more than \$7,000.



3rd Annual Brain Waves Swim Relay
San Diego, CA - October 1, 2011

The UCLA Neuro-Oncology Program is forever grateful to its donors, friends and supporters who have helped the UCLA Neuro-Oncology Program make significant strides in brain cancer research, bringing the world closer to a cure.

For those who are interested in participating in future fundraising events or information on how to start your own event, please call the UCLA Neuro-Oncology Program office at (310) 206-3610.



Art of the Brain 12th Annual Gala - “The Art of Care Giving”

Art of the Brain, a non-profit organization under the auspices of The UCLA Foundation, held its twelfth annual fundraising gala on Saturday, October 1, 2011 to honor brain cancer survivors and supporters, and to raise funds for brain cancer research headed by Dr. Timothy Cloughesy at the UCLA Neuro-Oncology Program.

The 2011 event celebrated “The Art of Caregiving” honoring caregivers, brain cancer survivors, past loved ones, and individuals who have made strides in research and philanthropy. Over 400 supporters attended the Gala.

To celebrate, the Art of the Brain held a reception offering musical entertainment by The Shpil, a raffle, hors d’oeuvres and desserts. Attendees were treated to a feast of culinary magic, fine wines and beverages, and desserts from the following establishments and supporters: Adelaida Cellars,

Always Cookin’ Catering, Balcom Family Cellars, Barney’s Beanery, Buddha’s Belly, Earth Wind & Flour, Friandise Pastries Inc., Gravel Nuts, DeMeo Family, Kate Mantilini, KFC, LA Gourmet, Pure Cheesecakes, Stan’s Donuts, The Coca-Cola Company, The Goodie Girls, UCLA Catering, Viktor Benes Bakery and Villacana Winery.

The evening’s program, which was co-produced by Dari Mackenzie and Annie Gerhart, opened with a musical performance by Dave Kinnoin singing “Character Counts,” honoring caregivers and the strength and courage they exemplify in caring for a loved one.

Jason Barry, a reporter for the Phoenix CBS-affiliate and whose father was a brain cancer patient of Dr. Cloughesy’s, was master of ceremony for the program.



Art of the Brain – Photos by Amir Kojoor
(Left) Stephen Petree onstage performance
(Top Right) Judi Kaufman and emcee Jason Barry
(Bottom Right) Tony Wertenbruch accepting the Judi Kaufman Founders Responsibility Award on behalf of his wife, Sherry Wertenbruch

Supporters were also treated to the musical stylings of Stephen Petree who performed original songs and opened his set with a cover of Jesus Jones' 'Right Here, Right Now' setting an inspirational tone to the show. Petree ended the show with an acoustic version of his original song 'You're Gonna Make It' offering a message of hope to those affected by brain cancer.

Also featured in the program was the presentation of the Judi Kaufman Founders Responsibility Award. Sherry Wertenbruch was the recipient of the award, with her husband Tony accepting on her behalf. This award recognizes those who have contributed to brain cancer research through philanthropy. Wertenbruch was an integral member of the Art of the Brain, serving as a member-at-large. She was part of the team that helped build Art of the Brain from the ground up since the organization's inception in the year 2000. Unfortunately, in December 2010, Sherry passed away.

The Johnny Mercer Foundation Research Award was also presented at the event to Dr. Phioanh (Leia) Nghiemphu, As-

sistant Professor at the UCLA Department of Neurology and Fellowship Program Director for the UCLA Neuro-Oncology Program. She was honored for her commitment to brain cancer research. Dr. Nghiemphu is a dedicated clinician whose research interests lies in individualized, targeted therapies for brain cancer patients. She is committed to brain cancer research in hopes of ultimately finding a cure, and is currently the principal investigator on a Phase II study on a combination therapy for elderly patients with GBM.

Since the organization's inception in 2000, Art of the Brain has raised more than \$4.2 million, with over \$432,459 raised in 2011. The Gala, itself, raised \$380,552. Money raised through Art of the Brain has provided funding for the training of several physician-scientists who have developed research projects aimed at eradicating brain cancer and also continues to support a number of ground-breaking clinical research studies.

The 2011 Gala would not have been a success without the support of its generous sponsors. <Continued p.18>

Art of The Brain – Continued

We would like to recognize our distinguished sponsors, and all those who generously supported the 2011 Art of the Brain 12th Annual Gala.

NETWORK SPONSOR : The Johnny Mercer Foundation

LEGACY SPONSORS: Robert & Jennifer Lopata, Afsaneh & Faramarz Yousefzadeh / STM Group, Inc.

COURAGE SPONSORS: Browning Automotive Group, City National Bank, Joan & Gerald Doren, Gang Tyre Ramer & Brown, Genentech, Inc, Greenberg Traurig, Judi & Roy Kaufman, Ann Ramer, Cookie Shapiro, The Beryl Companies

GRATITUDE SPONSORS: Richard Dean Anderson, Joyce & William Bromiley, Marlene & David Capell, Clint & Dina Eastwood, Valerie & Robert Fairbank, Fenton Grant Mayfield Kaneda & Litt, Gold Family Foundation, Karen & George Grengs / Valterra Products, Inc., Richard & Sue Masson, Mitra & Bahram Nabati / Pioneer Distributors, Inc., Bob & Virginia Newhart, Benedicta & Geoffrey Oblath, Mary Rooney, Ruby Family Foundation, StudioChic, LLC, The Barbera Hale Thornhill Fund, Gy & Judi Waldron, Bunny Wasser & Howard Bernstein, Wells Fargo, Cynthia & Bud Yorkin,

Art of the Brain is an organization dedicated to helping those who are affected with brain cancer through fundraising for brain cancer research at UCLA and also offering a support system for those in need through their Brain Buddies. For those who are interested in supporting Art of the Brain, either by volunteering or making a contribution, please visit the Art of the Brain website at www.artofthebrain.org or call (310) 825-5074.

UCLA Memorial Funds

Without the support of its generous donors, the UCLA Neuro-Oncology Program would not be able to make accelerated advancements in brain cancer research. Many of these donors have made contributions in tribute to our past patients and friends here at UCLA Neuro-Oncology. Below is a list of our memorial funds.

Thank you to the families and friends of those below who have supported brain cancer research at UCLA Neuro-Oncology. For information about making a contribution or creating a memorial fund, please call the UCLA Neuro-Oncology Program office at (310) 206-3610.



2012 Memorial Funds - UCLA Neuro-Oncology			
Katie Abbott Elizabeth Adler Arthur Allen, M.D. Terry Allen Allan Gregg Anderson June Anderson Scott Anderson Mark Ando Ron Antoine Robert Emmett Arthurs Tom Atkinson Shashi Bagai	John Baile Adam Balch Klaus Barth Lisa Barton Dorothy Beardman Hans Beer Rochelle Bergman Steven Birken Tom Bishop Joan Black Paul Bleschmidt James Bouchard	Ron Braschi Nancy Brodski Melvin Brody, M.D. George Ricky Brown Tanya Burger Robin Burks Scott Burtz Jackie Byrd Joshua Calderonello John Cannon Kevin Carlberg Salvatore Carota	Gerald Chazan Walter Churgin Mary Clark Jolly Cochetti Nancy Confar Joseph Copeland Carole Corey Theodore Coy Susan Crane Anthony Jerry Craveiro H. Eugene Crawford Martin Cronin

2012 Memorial Funds - Continued

Stephanie Crystal
Aida Dagort
Baldo Dal Ponte
Michael David
Ellen Davidson
Rod Davidson
Alex Demos
Clark Desser
Donna Dikes
Nancy Dorff
Florin Dumitra
Michael C. Dunn
Jeri Duvall
Yvonne Endicott
Charles English
Renata Ernst
Mark Estrin
Elsie Flores
Philip Freeman
Amnon Friedman
Fred Friedman
Ada Furth
Jessie Garrett
Kelly Garthoffner
Laurie Gaston
Jane Gekler
Roy Gerber
Andrea Geyer
John Gibbs
Laura Gipson
Lindsey Glassford
Joan Glick
Elisheva Goldstein
Armando Gonzalez
Edward Gorsuch
William Grahn
Kevin Green
Patricia Grengs
Richard Haff
Marie Halsey
Jerry Harms
Brian Harnack
Allyn Harrington
Stephen Harris

Russell Harrison
Sharon Harruff
James Hemann
Dolores Hernandez
James Hernquist
David Hettler
Maurita Hohman
Ralph Holt
Arthur Hopwood
John Houssels
James Hudspeth
Roger Hughes
Stephen Hulsy
Nancy Hunter
Ronn Iverson
John Jacobs
Lawrence Jacobs
Dennis Johnson
Peter Joseph
Richard Joswig
Richard Justice
Shodja Kargari
Paulette Katz
Jeannie Kauffman
Kathy Kaufman
Kishan Kooner
Bette Koupal
Satish Krishnan
Marlin Kurle
William Lackey
Douglas Laidlaw
Leonard Lazarus
Gerald Lillis
Barbara Lineberry
Lee Lobell
Clifford Locks
Basil Lombardo
Stephanie Lopez
Stuart Lough
Shirley Luedde
Jerry Lushing
Elsbeth Mahler
Jack Maloney
Tina Manaster

Marilyn Marks
Ron Martin
Francisco Martinez
Paulo Mattioli
Saeko Mayeda
Jesse Mazon
Meg Mazursky
Charles McCreight
James McDonald
Leon McDonald
Bronnie McNabb
Zane Melmed
Darryl Miller
Terry Miller
Todd Miller
Sandra Morrissey
Nellie Mortillaro
Tamara Muinos
Lloyd Nelson
Deborah Nielsen
Nancy Oard
Candice Orbach
Julietta C. Ortiz
Jonathan Panzer
Jean-Pierre Perez
Walter Peter
Richard Peterson
Sylvia Phelps
Joseph Pollard
Harry Printz
Mark Radcliffe
David Rankin
Kevin Riley
Larry Rissler
Nancy Rose
Gerald Roth
Catherine Rusher
Dani Saleh
Lisa Savoy
Mark Schackman
Dov Scharf
Russell Schwartzman
Barbara Scolnick
Kevin Sheedy

Timothy Sheehan
Christopher Sherrin
Connie Shur
Keith Sidley
Bernard Siegel M.D.
Ray Sifling
Ira Simon
Marvin Simon
Kurt Smith
Richard Smith
Victoria Smith
Mark Smuckler
Christopher Snaith
Jeffrey Snelson
Dottie Snyder
Arthur Sorosky, M.D.
Barry Spiegelman
Michael Srednick
Joseph Stewart
John Swanson
Al Teitelbaum
Ronn Teitelbaum
Mary Trawick
Brad Uecker
Denise Urban
Donald Van Steenwyk
Sharon Vandervort
Joan Vickery
Vina Villanueva
Geraldine Waldman
Robert Wearn
Chris Weisz
Sherry Wertenbruch
Jeffrey Wilcox
Heather Wimmer
Michael Woo
Capp Wormley
Lisa Young
Mark Zatzkis
Hank Zavaleta
Norman Zeller
Sigi Ziering
Irving Zimmelman

For more information about any of our Memorial Funds or if you would like to create or donate to a Memorial Fund, please call Luzianne Fernandez at (310) 206-3610.

UCLA to host 12th Annual Brain Tumor Conference

March 23rd & 24th 2012

Join brain tumor survivors, family members, friends and health care professionals at the Twelfth Annual Brain Tumor Conference, hosted by the UCLA Neuro-Oncology Program. This FREE conference will offer participants the opportunity to hear leading healthcare professionals speak about the latest treatments for brain tumors. Attendees will also have to chance to learn about symptom management, community resources and social support. Representatives from brain tumor organizations, health advocacy agencies, support groups and others will also be available to offer vital information and resources catering to the brain tumor community.

Free Conference Registration at <http://neurooncology.ucla.edu>

Friday, March 23, 2012 - GENERAL SESSIONS

8:00 am	Registration & Continental Breakfast
9:00 am	Welcome Note & Overview of Brain Tumors Speaker: Timothy F. Cloughesy, M.D. ; Director of UCLA Neuro-Oncology Program Professor, UCLA Department of Neurology
10:00 am	Neurosurgery Techniques Speaker: Linda Liau, M.D., Ph.D. ; Director of UCLA Malignant Brain Tumor Program Professor, UCLA Department of Neurosurgery
11:00 am	Radiation Treatments & Stereotactic Radiosurgery Speaker: Antonio F. DeSalles, M.D., Ph.D.; Director of UCLA Stereotactic Surgery Program Professor, UCLA Departments of Neursurgery & Radiation Oncology
12:00 pm	LUNCH
1:00 pm	Chemotherapy Speaker: Albert Lai, M.D., Ph.D.; UCLA Neuro-Oncology Program Assistant Professor-in-Residence, UCLA Department of Neurology
1:45 pm	Understanding Neuropathology Speaker: TBA
2:45 pm	Experimental Therapies: Clinical Trials & Biological Agents Speaker: Phioanh Nghiemphu, M.D. ; UCLA Neuro-Oncology Program Assistant Professor, UCLA Department of Neurology
3:30 pm	Brain Tumor Translational Resource: Tumor Banking Speaker: William H. Yong, M.D. ; Director of UCLA Brain Tumor Translational Resource Professor, UCLA Department of Pathology and Laboratory Medicine
4:00 pm	Imaging for Brain Tumors Speaker: Whitney Pope, M.D., Ph.D. ; Director of UCLA Brain Tumor Imaging Associate Professor, UCLA Department of Rodiological Sciences

Saturday, March 24, 2012 BREAKOUT SESSIONS

8:00 am	Registration & Continental Breakfast	
9:00 am	SESSION I:	A. Neuropsychology & Brain Tumors Speaker: Dr. Patricia Walshaw, UCLA Psychiatry and Biobehavioral Sciences B. Legal Issues: Employment & Benefits Speaker: Shawn Kravich, Esq., Cancer Legal Resource Center C. Complementary & Integrative Medicine Approaches Speaker: Dr. Mary Hardy, Medical Director of Simms/Mann Center at UCLA D. Seizure Management Speaker: Dr. David Piccioni and Dr. Ruben Guzman-Marin, UCLA Neuro-Oncology
10:00 am	SESSION II:	A. Symptom Management Speaker: Nanette Fong, Nurse Practitioner, UCLA Neuro-Oncology B. End of Life Issues Speakers: Dr. Leia Nghiemphu, UCLA Neuro-Oncology Cheryl Abe, LCSW, UCLA Oncology Center C. Integrating Psychosocial Support Into Treatment: "The Patient-Active Approach" Facilitator: Richard Hart, Cancer Support Community-Benjamin Center D. Tumor Type: Brain Metastasis Speaker: Dr. Timothy Cloughesy, UCLA Neuro-Oncology
11:00 am	SESSION III:	A. Nutrition for Brain Tumor Patients Speaker: Carolyn Katzin, MSPH, CNS B. Helping Children When A Parent Has A Brain Tumor Speakers: Bonnie Moore, LCSW & Kati Kern, LCSW C. Tumor Type: Pediatric Brain Tumors Speaker: Dr. Tom Belle Davidson, UCLA Pediatric Oncology D. Mindfulness Meditation Speaker: Lisa Kring, LCSW, Simms/Mann Center at UCLA
11:45 am	LUNCH	
12:45 pm	SESSION IV:	A. Understanding Clinical Trials B. Understanding Language Impairments Speaker: Dr. Susan Bookheimer, UCLA Psychiatry and Biobehavioral Sciences C. Understanding the Family Experience Facilitators: Cheryl Abe LCSW, UCLA Oncology Center Pamela Hoff LCSW, UCLA Radiation Oncology D. Legal Issues: Navigating Health Insurance Speaker: Shawn Kravich, Esq., Cancer Legal Resource Center E. Qi Gong Healing Exercise Speaker: Michael Sieverts
1:45pm	SESSION V:	A. Tumor Type: Glioblastoma Multiforme & Anaplastic Tumors Speaker: Dr. Timothy Cloughesy, UCLA Neuro-Oncology B. Tumor Type: Low Grade Tumors & Oligodendrogliomas Speaker: Dr. Albert Lai, UCLA Neuro-Oncology C. Tumor Type: Meningiomas Speaker: Dr. Richard Green, Director - Kaiser Los Angeles Neuro-Oncology D. Tumor Type: Rare Tumors (e.g. Medulloblastoma, Germinoma, Hemangioma, etc) Speaker: Dr. Phioanh Nghiemphu, UCLA Neuro-Oncology

PHYSICIAN CONSULT SESSIONS *(Friday, March 23, 2012 Only)*

Participants will also have the opportunity to register for a free 15-minute consultation with a participating physician specializing in neurooncology, neurosurgery, radiation-oncology or pediatric neurooncology. Here is your chance to meet and ask questions regarding your care, medical advice, etc.

Appointment slots to meet with one of our participating physicians are limited and only available on Friday, March 23rd. Those interested in a consultation should sign up upon arrival at the registration desk. Appointments will not be taken prior to the day of the event.

2012 BRAIN TUMOR CONFERENCE REGISTRATION FORM

Please complete this form and return to:
UCLA Brain Tumor Conference
c/o UCLA Neuro-Oncology Program
710 Westwood Plaza, RNRC Suite #1-230
Los Angeles, CA 90095

Registration forms may also be faxed to (310) 825-0644 or (310) 267-1292.
For questions regarding the conference or registration, please call (310) 206-3610.
Online registration will be available at www.neurooncology.ucla.edu

Registration Deadline via Fax and Online is Tuesday, March 20, 2012.
Registrations sent via mail must be postmarked by Saturday, March 17, 2012.

***If registering family members or companions, please complete a separate registration form for each attendee.

FIRST NAME _____ LAST NAME _____

I AM A: ☐ patient ☐ caregiver ☐ family member ☐ healthcare professional ☐ other: _____

ADDRESS _____

CITY _____ STATE _____ ZIP CODE _____

TELEPHONE/MOBILE PHONE # _____ FACSIMILE # _____

EMAIL ADDRESS _____

PLEASE INDICATE WHICH SESSION(S) YOU PLAN TO ATTEND FOR EACH DAY

FRIDAY, MARCH 23, 2012 GENERAL SESSIONS

- | | |
|--|--|
| ☐ 9:00 am Welcome & Overview of Brain Tumors | ☐ 10:00 am Neurosurgery Techniques |
| ☐ 11:00 am Radiation Therapies | ☐ 1:00 pm Chemotherapy |
| ☐ 1:45 pm Neuropathology | ☐ 2:45 pm Experimental Therapies |
| ☐ 3:30 pm Tumor Banking | ☐ 4:00 pm Brain Tumor Imaging |

SATURDAY, MARCH 24, 2012 BREAKOUT SESSIONS (please choose ONLY ONE from each session)

- | | | |
|------------------------|---|---|
| SESSION I - 9:00 am | ☐ A. Neuro-Psychology | ☐ B. Employment & Benefits |
| | ☐ C. Complementary Medicine | ☐ D. Seizure Management |
| SESSION II - 10:00 am | ☐ A. Symptom Management | ☐ B. End of Life Issues |
| | ☐ C. Integrating Psychosocial Support | ☐ D. Brain Metastasis |
| SESSION III - 11:00 am | ☐ A. Nutrition | ☐ B. Helping Childing When Parent Has Tumor |
| | ☐ C. Pediatric Brain Tumors | ☐ D. Mindfulness Meditation |
| SESSION IV - 12:45 pm | ☐ A. Understanding Clinical Trials | ☐ B. Understanding Language Impairments |
| | ☐ C. Understanding Family Experience | ☐ D. Navigating Health Insurance |
| | | ☐ E. Qi Gong Healing Exercise |
| SESSION V - 1:45 pm | ☐ A. GBM/Anaplastic Tumors | ☐ B. Low Grade & Oligodendrogliomas |
| | ☐ C. Meningiomas | ☐ D. Rare Tumors |


DO YOU REQUIRE A VEGETARIAN MEAL? yes no

DO YOU REQUIRE SPECIAL ASSISTANCE? yes no Please Specify: _____

ARE YOU CURRENTLY RECEIVING TREATMENT AT UCLA? yes no

HOW DID YOU HEAR ABOUT THIS CONFERENCE? _____

2012 BRAIN TUMOR CONFERENCE ~ MAP & DIRECTIONS



VENUE LOCATION:

UCLA Covell Commons
3rd Floor
330 De Neve Drive
Los Angeles, CA 90095

PARKING:

Parking Structure Sunset Village
(PSV)
Daily Parking Permit is \$11
Daily Disabled Parking Permit is \$4

DIRECTIONS

- Take the San Diego Freeway (I-405)
- Exit Sunset Blvd EAST
- Proceed EAST on Sunset Blvd, past Veteran Avenue
- Turn RIGHT at Bellagio Drive
- At top of hill, make a LEFT at the stop
- Continue down the road and Sunset Village Parking Structure will be on your Right.
- From 7am to 12pm, purchase a daily parking permit from the parking attendant stationed at the gate.
- **After 12pm on Friday**, please proceed to the UCLA Information and Parking Kiosk located off of **Sunset & Westwood in the Parking Lot 4 Entrance** to purchase a parking pass.
- **After 12pm on Saturday**, please proceed to the UCLA Information and Parking Kiosk located on **Westwood Plaza & Strathmore Drive** to purchase a parking pass.
- From the Sunset Village parking structure, take the elevator to the Lobby level.
- Covell Commons will be directly in front upon exiting the elevator. Follow signage to the conference.
- In the event that the Sunset Village Parking Structure fills, please park in Parking Lot 7.

HOTEL ACCOMODATIONS

There are several surrounding hotels available for accommodations during the conference. The hotels listed below are independent businesses with no affiliation to UCLA Neuro-Oncology Program. We list these accommodations for the convenience of our conference attendees.

UCLA GUEST HOUSE	(310) 825-2923
HILGARD HOUSE HOTEL	(310) 208-3945
UCLA TIVERTON HOUSE	(310) 794-0151
CLAREMONT HOTEL	(310) 208-5957
THE W HOTEL	(310) 208-8765
ROYAL PALACE WESTWOOD	(310) 208-6677
ANGELENO HOTEL	(310) 476-6411
LUXE HOTEL SUNSET BLVD	(310) 476-6571

UCLA Neuro-Oncology Program
710 Westwood Plaza, Reed Bldg, RM 1-230
Los Angeles, CA 90095
NFG6

FIRST CLASS MAIL
U.S. POSTAGE

PAID

UCLA



Ronald Reagan UCLA Medical Center rated one of top hospitals in the U.S. Ranked 'Best in West' for 22nd consecutive year

UCLA 12th Annual Brain Tumor Conference March 23rd & 24th 2012

FREE REGISTRATION

Join brain tumor survivors, family members, friends and health care professionals at the 12th Annual Brain Tumor Conference, hosted by the UCLA Neuro-Oncology Program.

Registration Deadline: March 20th, 2012

FREE Conference Registration at
<http://neurooncology.ucla.edu>

For more information about upcoming clinical trials currently being offered by the UCLA Neuro-Oncology Program, please contact our Clinical Trials team at (310) 794-3521

Visit us at:
<http://neurooncology.ucla.edu>

For more information on Patient Services, Care Giver Support Groups and recent findings.

